Please login to the form below

Not currently logged in
Email:
Password:

immuno-oncology

This page shows the latest immuno-oncology news and features for those working in and with pharma, biotech and healthcare.

CRUK forges £30m ‘post-Brexit’ R&D alliance

CRUK forges £30m ‘post-Brexit’ R&D alliance

funding towards translational research projects in cancer and particularly immuno-oncology.

Latest news

  • AZ nabs US approval for new leukaemia drug Lumoxiti AZ nabs US approval for new leukaemia drug Lumoxiti

    AZ nabs US approval for new leukaemia drug Lumoxiti. Adds to firm's growing oncology franchise. ... It has assumed greater importance for the targeted pipeline – which sits alongside AZ’s immuno-oncology R&D – since MEK Inhibitor selumetinib failed

  • Boehringer bolts on another immuno-oncology company Boehringer bolts on another immuno-oncology company

    Boehringer bolts on another immuno-oncology company. Acquires ViraTherapeutics in a 210m takeover deal. ... The drugmaker says the viral therapy has shown promising results in combination with its other immuno-oncology programmes.

  • Affimed rockets on $5bn-plus Roche immuno-oncology deal Affimed rockets on $5bn-plus Roche immuno-oncology deal

    Affimed rockets on $5bn-plus Roche immuno-oncology deal. Swiss pharma giant set to pay $96m upfront to discover new cancer immunotherapies. ... Roche – which is already an emerging player in immuno-oncology with its Tecentriq (atezolizumab) PD-L1

  • Novartis wins key adjuvant Taf/Mek approval in Europe Novartis wins key adjuvant Taf/Mek approval in Europe

    The new indication – the third for the BRAF/MEK inhibitor combination – is an important one for Novartis as it faces increasing competition in the melanoma market from immuno-oncology drugs like

  • AbbVie to develop argenx-partnered GARP-targeted immunotherapy AbbVie to develop argenx-partnered GARP-targeted immunotherapy

    Abbott Laboratories spin-out AbbVie has announced plans to start developing and commercialising a new immuno-oncology drug, building on an initial deal with European biotech argenx. ... Tom Hudson, Vice President, Oncology Early Discovery and Development,

More from news
Approximately 61 fully matching, plus 238 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 3 fully matching, plus 45 partially matching documents found.

Latest appointments

  • BMS appoints CCO, Stephen Davies joins Eisai and more BMS appoints CCO, Stephen Davies joins Eisai and more

    There, he led the discovery of novel immuno-oncology and autoimmune therapeutic programmes. ... class new treatments for cancer patients and to help transform the company into a world-class immuno-oncology leader.".

  • Redx Pharma appoints new chief medical officer Redx Pharma appoints new chief medical officer

    Dr Saunders has worked in the oncology field for over 25 years and has experience in all aspects of the clinical development of oncology drugs. ... He joins the UK biotech from Lytix Biopharma, a Norweigan immuno-oncology biotech, where he also served as

  • Targovax appoints Michael Bogenstaetter as chief business officer Targovax appoints Michael Bogenstaetter as chief business officer

    Targovax appoints Michael Bogenstaetter as chief business officer. He joins the immuno-oncology biotech from Interim Assignments.

  • Lilly bolsters its oncology team Lilly bolsters its oncology team

    Lilly bolsters its oncology team. Kimberly Blackwell is appointed VP early phase development, immuno-oncology. ... Furthermore, she has been on the forefront of research in oncology vaccines, immuno-oncology and biosimilars, giving her the unique

  • BMS’ Dr Mike Burgees joins Turnstone Biologics BMS’ Dr Mike Burgees joins Turnstone Biologics

    BMS’ Dr Mike Burgees joins Turnstone Biologics. He joins the immuno-oncology group as its president of R&D. ... Mike’s oncology expertise will be instrumental in advancing the development of our next-generation viral immunotherapies and powerful

More from appointments
Approximately 0 fully matching, plus 31 partially matching documents found.

Latest from PMHub

  • SWITCHED ONcology

    We are stronger together. We are Switched ON. Switched ONcology is the latest thought leadership campaign from the award-winning Havas lynx portfolio. ... The campaign provides our partners with deeper insight, smarter ideas and more meaningful

  • The Big Communication - matching unprecedented clinical advances in immunotherapy with transformative communication

    In this white paper, we explore the exciting new frontier of cancer treatment - immuno-oncology (IO) - and what it means for how we communicate with healthcare professionals, patients and carers.

  • Medical information in precision medicine

    We are not treating the partnership as just another oncology medicine – it’ s a molecular information service, and that requires a great level of scientific understanding.

  • Video: Immuno-oncology therapies

    Video: Immuno-oncology therapies. Immuno-oncology therapies which harness the body’ s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. ... In this video Director Sue Marett discusses the opportunities

  • Video: Immuno-oncology therapies

    Video: Immuno-oncology therapies. Immuno-oncology therapies which harness the body’ s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. ... In this video Director Sue Marett discusses the opportunities

More from PMHub
Approximately 20 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics